PD-L1 (22C3) Dako CPS IHC Test – Accurate Immunohistochemistry for Cancer Diagnosis

Description

The PD-L1 (22C3) Dako CPS (IHC) Test is a highly specialized immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor tissue, providing critical insights for personalized cancer treatment decisions. This test utilizes the 22C3 monoclonal antibody to detect programmed death-ligand 1 (PD-L1) expression in both tumor cells and immune cells, generating a Combined Positive Score (CPS) that helps guide the use of immune checkpoint inhibitors such as anti-PD-1/PD-L1 therapies.

### Key Features:
✔ Validated for Clinical Decision-Making – Approved for use in multiple cancer types, including non-small cell lung cancer (NSCLC), gastric cancer, cervical cancer, and urothelial carcinoma.
✔ Quantitative CPS Scoring – Provides a precise and reproducible PD-L1 expression score**, ensuring accurate patient stratification for immunotherapy eligibility.
✔ High Sensitivity & Specificity – The 22C3 clone is optimized for Dako Autostainer Link 48, delivering consistent and reliable staining results.
✔ Standardized Interpretation – Enables pathologists to assess PD-L1 expression in both tumor and immune cells, ensuring a comprehensive evaluation of the tumor microenvironment.
✔ Proven Clinical Utility – Backed by extensive clinical trials, this test is a gold standard for determining PD-L1 expression in patients who may benefit from immune checkpoint inhibitors.

### Benefits & Value:
🔹 Optimized for Immunotherapy Selection – Helps oncologists **identify patients most likely to respond** to PD-1/PD-L1 inhibitors, improving treatment outcomes.
🔹 Enhances Precision Medicine – Supports a personalized approach to cancer care, ensuring that patients receive the most effective therapy based on their tumor’s PD-L1 status.
🔹 Reduces Unnecessary Treatments – By accurately assessing PD-L1 expression, the test helps avoid ineffective therapies, minimizing unnecessary side effects and costs.
🔹 Trusted by Leading Institutions – Used in global clinical trials and routine diagnostics, ensuring confidence in results for both clinicians and patients.

The PD-L1 (22C3) Dako CPS (IHC) Test is an essential tool in modern oncology, empowering clinicians with critical biomarker insights to drive more effective, targeted cancer treatments.